Camila Maríngolo Ribeiro

Universidade Estadual Paulista (UNESP). Campus de Araraquara. Faculdade de Ciências Farmacêuticas (FCFAR) (Institutional affiliation from the last research proposal)
Birthplace: Brazil

Abstract
According to the World Health Organization (WHO), 10.4 million people developed tuberculosis (TB) in 2016, the infectious disease that kills more people in the world than HIV / AIDS. The factor that aggravates this scenario is the progression of resistant strains of antibiotics available for treatment. One of the factors contributing to the emergence of strains resistant to antibiotics is…
Evaluation of in vitro and in vivo potential of siderophores-functionalized liposomes containing moxifloxacin against Mycobacterium tuberculosis, BP.DR
Abstract
In this project, we propose to evaluate the pharmacological interactions and possible synergistic effects of rifampin, isoniazid, amikacin, moxifloxacin, and five new furoxanic molecules obtained by the synthesis in LAPDESF (Laboratory of Drug Research and Development)at FCFAR/UNESP, which demonstrated promising against Mycobacterium tuberculosis. This project is part of the Young Researc…
Evaluation of pharmacological interaction and bactericidal kinetics of new furoxanic molecules in combination with rifampicin, isoniazid, amikacin, and moxifloxacin against Mycobacterium tuberculosis H37Rv, BP.IC

Source:Lattes Curriculum

CV Lattes ORCID

2 / 2	Completed scholarships in Brazil

Associated processes

Short URL

Abstract

Abstract